Navigation Links
Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
Date:10/30/2007

,095 178,179

-------------------------------------------------------------------------

Manufacturing and related process

development expenses 879,937 1,259,716

-------------------------------------------------------------------------

-------------------------------------------------------------------------

During the third quarter of 2007, our M&P expenses decreased to $879,937 compared to $1,259,716 for the third quarter of 2006. In the third quarter of 2007, we continued to fill, test, and package the REOLYSIN(R) that was produced earlier in the year. During the third quarter of 2006, we commenced a number of cGMP production runs using our improved manufacturing process. The technology transfer of our improved process was successfully completed at the beginning of the third quarter of 2006.

Our process development studies in the third quarter of 2007 focused on increasing the scale of our production runs from batch sizes of 20 litres to 40 and then 100 litres. In the third quarter of 2006, we completed process development studies that were successful in improving virus yields.

Clinical Trial Program

2007 2006

$ $

-------------------------------------------------------------------------

Direct clinical trial expenses 1,201,557 639,719

Other clinical trial expenses 76,618 48,716

-------------------------------------------------------------------------

Clinical trial expenses 1,278,175 688,435

-------------------------------------------------------------------------

-------------------------------------------------------------------------

During the third quarter of 2007, our direct clinical trial expenses increa
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... (PRWEB) March 29, 2015 A two-day ... United States and plenary talks by four leading photonics ... Optics + Optoelectronics next month in Prague, Czech ... in 17 conferences alongside a two-day exhibition. Sponsored by ... , the event will run 13-16 April in the ...
(Date:3/30/2015)... , March 30, 2015  Naldemedine, an investigational ... by Shionogi & Co., Ltd., met its primary ... (COMPOSE I) for the treatment of opioid-induced constipation ... receiving opioid therapy. Study results showed that naldemedine ... improved the frequency of spontaneous bowel movement (SBM) ...
(Date:3/30/2015)... , March 30, 2015  FUJIFILM Holdings Corporation ... Cellular Dynamics International, Inc. (CEO: Robert J. Palay ... and manufacturer of fully functioning human cells in industrial ... companies have entered into a definitive agreement whereby Fujifilm ... be followed by a second step merger. Fujifilm aims ...
(Date:3/29/2015)... Texas , March 29, 2015 /PRNewswire/ ... of study data in small cell cervical ... using Caris Molecular Intelligence®, the company,s panomic, ... certain gene mutations which may explain sensitivities ... found that identification of certain biomarkers may ...
Breaking Biology Technology:Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3
... , Harness the Dual Benefits of Freshly Isolated Plateability and ... In today,s competitive environment and economic climate, the financial ... drug compound or chemical entity cannot be underestimated. Researchers and ... with less, and productivity and cost savings are at a ...
... SHENYANG, China, June 16 /PRNewswire-Asia-FirstCall/ ... ) ("A-Power" or "the Company"), a,leading provider of distributed ... of wind turbines, today announced it has signed a,contract ... systems using biomass as fuel in Henan Province of,China. ...
... SYDNEY, June 16 /PRNewswire-Asia/ -- Pharmaceutical company Pharmaxis,(ASX: PXS; Nasdaq: ... results of its,recently completed international Phase III trial of Bronchitol ... European Cystic Fibrosis,Conference in Brest, France. , ... 12 June by Dr Diana,Bilton of the Royal Brompton Hospital, ...
Cached Biology Technology:Celsis Outlines the Top Five Advantages of Cryo-plateable Hepatocytes 2Celsis Outlines the Top Five Advantages of Cryo-plateable Hepatocytes 3Celsis Outlines the Top Five Advantages of Cryo-plateable Hepatocytes 4A-Power Energy Generation Systems Ltd. Signs a Biomass-Based DG Contract with Sanmenxia New Energy Bio-Electricity Co., Ltd. 2A-Power Energy Generation Systems Ltd. Signs a Biomass-Based DG Contract with Sanmenxia New Energy Bio-Electricity Co., Ltd. 3Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 2Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 3Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 4
(Date:3/23/2015)... , March 23, 2015  In the 2014 ... fraud case conviction losses. This figure accounts for a ... according to The Nilson Report, exceeds $11 billion globally. ... tool after a crime has occurred. Investor Mark ... polygraph expert Joe Paolella partnered to administer ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ... "India Sensors Market Forecast and Opportunities 2020" ... market is projected to grow at a CAGR ... automotive, industrial and healthcare sectors are the key ... addition, adoption of MEMS technology in sensors is ...
(Date:3/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces its biometric ... the products featured in 2015 "I Want That" International ... EST on the DIY Network.   DIY,s ... , site of the 2015 International CES for ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... production in algae, scientists at the U.S. Department of Energy,s ... metabolism by feeding them more carbon increases oil production as ... in the journal Plant and Cell Physiology on ... turn photosynthetic green algae into tiny "green factories" for producing ...
... Researchers have unveiled a novel strategy for neutralizing unwanted ... The strategy employs chains of binding agents, like "beads ... or more pathogenic molecules to neutralize their activity and ... low-cost, easy-to-replicate tool has demonstrated applications against several different ...
... Texas Children,s Hospital have identified commensal bacteria in ... may play a role in preventing or treating ... "We identified, to our knowledge, the first bifidobacterial ... large amounts of gamma-aminobutyric acid (GABA). This ...
Cached Biology News:Carbon is key for getting algae to pump out more oil 2Carbon is key for getting algae to pump out more oil 3Antitoxin strategy may help target other pathogens 2Antitoxin strategy may help target other pathogens 3Intestinal bacteria produce neurotransmitter, could play role in inflammation 2